Researchers from the University of Missouri School of Medicine have developed panels of protein biomarkers present in teens and young adults that distinguish individuals with healthy hips from those with developmental dysplasia of the hip, also known as hip dysplasia, which often progresses to hip osteoarthritis if not recognized before early adulthood.
The researchers tested standard blood and urine samples for the presence of targeted protein biomarkers and discovered that specific protein combinations were consistently different between patients with hip dysplasia when compared to age-matched individuals with healthy hips. Clinical application of these tests could enable early and accurate diagnosis for this common hip ailment. This would be a major improvement over current diagnostic methods and allow for implementation of optimal prevention and treatment strategies that could help some patients avoid hip replacement surgery later in life.
“The results from this study suggest that these biomarker panels could be further developed into routine lab tests that help physicians accurately identify patients with hip dysplasia so that nonsurgical and surgical joint preservation treatments can be implemented when they are most effective,” said senior author James Cook, DVM, PhD, William & Kathryn Allen Distinguished Chair in Orthopaedic Surgery and director of the Thompson Laboratory for Regenerative Orthopaedics. “Further optimization of these biomarker panels could result in highly effective tools that significantly decrease the number of patients who suffer from debilitating hip osteoarthritis as they age.”
The researchers collected blood and urine samples from 13-to-34-year-old patients with physician confirmed developmental dysplasia of the hip along with a control group of 13-to 34-year-old volunteers with healthy hips. Panels including serum and urine biomarkers differentiated the two groups with high degrees of sensitivity and specificity.
The biomarker differences between the two groups suggest that hips with developmental dysplasia before the onset of osteoarthritis of the hip are mechanistically distinct from healthy hips in terms of inflammatory and joint remodeling processes that typically lead to osteoarthritis if left untreated.
Osteoarthritis is the primary reason that patients opt for total hip replacement surgery.
“The potential to screen young individuals at-risk for hip problems could aid nonsurgical treatment interventions earlier in life rather than developing arthritis,” said Brett Crist, MD, professor of Orthopaedic Surgery. “Based upon the ease of sample collection, this panel could be readily incorporated into clinical practice as a screening tool for future risk of hip problems.”
Along with Cook and Crist, the research team included Preston Wolfe, PhD, Aaron Stoker, PhD, Emily Leary, PhD and Chantelle Bozynski, DVM, MSc, DACVP, of the Thompson Laboratory for Regenerative Orthopaedics at the University of Missouri.
“Evaluation of Serum and Urine Biomarker Panels for Development Dysplasia of the Hip before Onset of Secondary Osteoarthritis” was recently published in Cartilage. The study was approved by the University of Missouri Institutional Review Board and informed consent was documented for all patients involved.
Method of Research
Subject of Research
Evaluation of Serum and Urine Biomarker Panels for Developmental Dysplasia of the Hip Prior to Onset of Secondary Osteoarthritis
Article Publication Date
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Preston N. Wolfe is a full-time employee with Arthrex, Inc. • Brett D. Crist is a board or committee member for AO Trauma North America: Board or committee member; receives IP royalties from Globus Medical; is a board or committee member for International Geriatric Fracture Society; is on the editorial or governing board of the Journal of Hip Preservation and Journal of Orthopedic Trauma; is a paid presenter or speaker for KCI; has stock or stock options for Orthopedic Implant Company; is a board or committee member for Orthopedic Trauma Association; is an unpaid consultant for Osteocentric; has stock or stock options for RomTech; is on the editorial or governing board for SLACK Incorporated; receives publishing royalties, financial or material support from Springer; is a paid consultant and receives research support from Synthes. • Aaron M. Stoker receives IP royalties from Musculoskeletal Transplant Foundation • Emily Leary is on the editorial or governing board for JISAKOS and The Journal of Knee Surgery • James L. Cook is a paid consultant, paid presenter or speaker and receives research support from Arthrex, Inc; is a paid consultant for Bioventus; receives research support from the Coulter Foundation; receives research support from DePuy, A Johnson & Johnson company; receives research support from GE Healthcare; is on the editorial or governing board of the Journal of Knee Surgery; receives research support from Merial; is a board or committee member for Midwest Transplant Network; is a board or committee member, receives IP royalties and research support from Musculoskeletal Transplant Foundation; receives research support from National Institutes of Health (NIAMS and NICHD); receives research support from Purina; receives publishing royalties, financial or material support from Thieme; is a paid consultant for Trupanion; and receives research support from the U.S. Department of Defense. Chantelle Bozynski has no conflict of interest(s) to disclose.
Watafiti kutoka Chuo Kikuu cha Missouri School of Medicine wametengeneza paneli za biomarker za protini zilizopo katika matineja na watu wazima vijana ambao hutofautisha watu wenye viuno vyenye afya kutoka kwa wale walio na dysplasia ya maendeleo ya viuno, ambayo mara nyingi huendelea kuwa osteoarthritis ya viuno ikiwa haijatambuliwa kabla ya watu wazima. Watafiti walichunguza sampuli za kawaida za damu na mkojo kwa uwepo wa biomarker za protini za lengo na kugundua kwamba mchanganyiko maalum wa protini ulikuwa tofauti kati ya wagonjwa wenye dysplasia ya kiuno ikilinganishwa na watu wenye umri sawa na viuno vyenye afya. Matumizi ya kliniki ya vipimo hivi yanaweza kuwezesha utambuzi wa mapema na sahihi wa ugonjwa huu wa kawaida wa kiuno. Hii itakuwa uboreshaji mkubwa juu ya mbinu za sasa za utambuzi na kuruhusu utekelezaji wa mikakati bora ya kuzuia na matibabu ambayo inaweza kusaidia baadhi ya wagonjwa kuepuka upasuaji wa uingizaji wa kiuno baadaye maishani. "Matokeo ya utafiti huu yanaonyesha kwamba paneli hizi za biomarker zinaweza kuendelezwa zaidi katika vipimo vya kawaida vya maabara ambavyo husaidia madaktari kutambua kwa usahihi wagonjwa wenye dysplasia ya kiuno ili matibabu ya kuhifadhi pamoja yasiyo ya upasuaji na ya upasuaji yaweze kutekelezwa wakati yanafaa zaidi, ""alisema mwandishi mwandamizi James Cook, DMD, PhD, William & Kathryn Allen Distinguished Chair katika Upasuaji wa Orthopaedic na Mkurugenzi wa Maabara ya Thompson ya Orthopaedics ya Regenerative." "Utaratibu huu wa ""kuongeza"" kwa viashiria vya viungo vya mwili unaweza kuathiri idadi ya watu wanaosumbuliwa na ugonjwa wa hip osteoarthritis, na watafiti walichukua sampuli za damu na mkojo kutoka kwa wagonjwa wa miaka 13-34 na daktari alithibitisha dysplasia ya maendeleo ya viungo vya mwili pamoja na kikundi cha udhibiti wa kujitolea wa miaka 13-34 na viungo vya mwili vyenye afya." Paneli ikiwa ni pamoja na biomarkers serum na mkojo tofauti makundi mawili na digrii ya juu ya unyeti na maalum. Tofauti za biomarker kati ya makundi mawili yanaonyesha kwamba viuno vyenye dysplasia ya maendeleo kabla ya kuanza kwa osteoarthritis ya viuno ni tofauti na viuno vyenye afya katika suala la mchakato wa uchochezi na marekebisho ya pamoja ambayo kwa kawaida husababisha osteoarthritis ikiwa haijatibiwa. Osteoarthritis ni sababu kuu ambayo wagonjwa huchagua upasuaji wa kubadilisha kiuno kabisa. "Uwezekano wa kuchunguza vijana walio hatarini kwa matatizo ya kiuno unaweza kusaidia uingiliaji wa matibabu yasiyo ya upasuaji mapema maishani badala ya kuendeleza ugonjwa wa viungo, "alisema Brett Crist, MD, profesa wa upasuaji wa mifupa. "Kutokana na urahisi wa ukusanyaji wa sampuli, jopo hili linaweza kuingizwa kwa urahisi katika mazoezi ya kliniki kama chombo cha uchunguzi wa hatari ya baadaye ya matatizo ya kiuno. "" Pamoja na Cook na Crist, timu ya utafiti ilijumuisha Preston Wolfe, PhD, Aaron Stoker, PhD, Emily Leary, PhD na Chantelle Bozinski, DVM, MSc, DACVP, wa Maabara ya Thompson ya Orthopedics ya Regenerative katika Chuo Kikuu cha Missouri." <unk> Tathmini ya Serum na Mkojo Biomarker Panels kwa ajili ya Maendeleo Dysplasia ya hip kabla ya mwanzo wa sekondari Osteoarthritis <unk> hivi karibuni ilichapishwa katika Cartilage. Utafiti huo ulikubaliwa na Bodi ya Mapitio ya Taasisi ya Chuo Kikuu cha Missouri na idhini ya kufahamu ilirekodiwa kwa wagonjwa wote waliohusika. "Mwandishi wa makala hii, Robert W. Wolfe, ni mwanachama wa bodi ya AO Trauma, Inc. (Bodi ya Bodi au Kamati ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya Bodi ya B "Mwanamke huyo, ambaye pia ni Mkurugenzi wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa Utafiti wa U Chantelle Bozynski hana mgogoro wa maslahi ya kufunua.